Fig 1.

CONSORT diagram. DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MTD, maximum-tolerated dose; q4wk, every 4 weeks. (*) An additional patient was enrolled over the six planned patients because one patient was unevaluable for safety (increased aminotransferase levels at screening in violation of study eligibility criteria and confirmed alcohol abuse). (†) All patients who received one or more doses of rituximab plus inotuzumab ozogamicin. One patient with DLBCL who was enrolled onto part 2 did not receive study treatment. (‡) All patients enrolled to receive MTD treatment (intent-to-treat): seven in part 1, 104 in part 2. One patient with DLBCL enrolled onto part 2 did not receive study treatment.